Paradigm Biocapital Advisors LP: TANGO THERAPEUTICS INC (TNGX): Quarterly 13F Position History
As of Q2 2026, Paradigm Biocapital Advisors LP reported 6,357,523 shares of TANGO THERAPEUTICS INC (TNGX), worth $198.7M and representing 3.7% of its 13F equity book. Quarter-over-quarter share count change: + 2,347,844 (+58.6%) . The position first appeared in Q3 2025 and has been disclosed across 4 13F-HR filings in Pactolio's tracked window.
- 6,357,523Shares Held (Latest Filing)
- $198.7MReported Market Value (Latest Filing)
- 3.7%Portfolio Weight (% of 13F Equity Book)
- +2,347,844Quarter-over-Quarter Share Change
- +$114.9MQuarter-over-Quarter Value Change
- 6,357,523Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,357,523 | +2,347,844 | +58.6% | $198.7M | 3.7% | $31.3 |
| Q1 2026 | 4,009,679 | +4,009,679 | – | $83.9M | 1.7% | $20.9 |
| Q4 2025 | 0 | 3,086,184 | -100.0% | $0 | 0.0% | – |
| Q3 2025 | 3,086,184 | – | – | $25.9M | 0.8% | $8.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a TNGX position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported TANGO THERAPEUTICS INC (TNGX) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in TNGX?
Between Q1 2026 and Q2 2026, Paradigm Biocapital Advisors LP added 2,347,844 shares of TNGX (+58.6%), bringing the total reported position to 6,357,523 shares at a market value of $198.7M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in TNGX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.